Influence of cannabis use on incidence of psychosis in people at clinical high risk-Reference-Cited by-全球学者库

Influence of cannabis use on incidence of psychosis in people at clinical high risk

Published:2023-05-13 Issue:9 Volume:77 Page:469-477
ISSN:1323-1316
Container-title:Psychiatry and Clinical Neurosciences
language:en
Short-container-title:Psychiatry Clin Neurosci

Author:

Chester Lucy A.¹^ORCID,Valmaggia Lucia R.²^ORCID,Kempton Matthew J.¹^ORCID,Chesney Edward¹^ORCID,Oliver Dominic¹³^ORCID,Hedges Emily P.¹⁴^ORCID,Klatsa Elise¹,Stahl Daniel⁵^ORCID,van der Gaag Mark⁶⁷^ORCID,de Haan Lieuwe⁸⁹^ORCID,Nelson Barnaby¹⁰¹¹^ORCID,McGorry Patrick¹⁰¹¹^ORCID,Amminger G. Paul¹⁰¹¹^ORCID,Riecher‐Rössler Anita¹²^ORCID,Studerus Erich¹³^ORCID,Bressan Rodrigo¹⁴^ORCID,Barrantes‐Vidal Neus¹⁵^ORCID,Krebs Marie‐Odile¹⁶^ORCID,Glenthøj Birte¹⁷^ORCID,Nordentoft Merete¹⁸^ORCID,Ruhrmann Stephan¹⁹^ORCID,Sachs Gabriele²⁰^ORCID,McGuire Philip¹³^ORCID,

Affiliation:

1. Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience King's College London London UK

2. Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience King's College London London UK

3. Department of Psychiatry Oxford University, Warneford Hospital Oxford UK

4. Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience King's College London London UK

5. Department of Biostatistics, Institute of Psychiatry, Psychology & Neuroscience King's College London London UK

6. Faculty of Behavioural and Movement Sciences, Department of Clinical Psychology and EMGO+ Institute for Health and Care Research VU University Amsterdam The Netherlands

7. Department of Psychosis Research Parnassia Psychiatric Institute The Hague The Netherlands

8. Department Early Psychosis Amsterdam UMC Amsterdam The Netherlands

9. Arkin Amsterdam Amsterdam The Netherlands

10. Centre for Youth Mental Health University of Melbourne Parkville Victoria Australia

11. Orygen Parkville Victoria Australia

12. Faculty of Medicine University of Basel Basel Switzerland

13. Department of Psychology, Division of Personality and Developmental Psychology University of Basel Basel Switzerland

14. LiNC—Lab Interdisciplinar Neurociências Clínicas, Depto Psiquiatria, Escola Paulista de Medicina Universidade Federal de São Paulo – UNIFESP Sao Paulo Brazil

15. Departament de Psicologia Clínica i de la Salut Universitat Autònoma de Barcelona, Fundació Sanitària Sant Pere Claver (Spain), Spanish Mental Health Research Network (CIBERSAM) Barcelona Spain

16. Hôpital Sainte‐Anne, C'JAAD, Service Hospitalo‐Universitaire, Inserm U894, Institut de Psychiatrie (CNRS 3557) University Paris Descartes Paris France

17. Centre for Neuropsychiatric Schizophrenia Research (CNSR) & Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup University of Copenhagen Glostrup Denmark

18. Mental Health Center Copenhagen and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, Mental Health Services in the Capital Region of Copenhagen University of Copenhagen Kobenhavn Denmark

19. Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital University of Cologne Cologne Germany

20. Department of Psychiatry and Psychotherapy Medical University of Vienna Wien Austria

Abstract

AimsEvidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However, there have been limited prospective studies and the direction of this association remains controversial. The primary aim of the present study was to examine the association between cannabis use and the incidence of psychotic disorders in people at clinical high risk of psychosis. Secondary aims were to assess associations between cannabis use and the persistence of psychotic symptoms, and with functional outcome.MethodsCurrent and previous cannabis use were assessed in individuals at clinical high risk of psychosis (n = 334) and healthy controls (n = 67), using a modified version of the Cannabis Experience Questionnaire. Participants were assessed at baseline and followed up for 2 years. Transition to psychosis and persistence of psychotic symptoms were assessed using the Comprehensive Assessment of At‐Risk Mental States criteria. Level of functioning at follow up was assessed using the Global Assessment of Functioning disability scale.ResultsDuring follow up, 16.2% of the clinical high‐risk sample developed psychosis. Of those who did not become psychotic, 51.4% had persistent symptoms and 48.6% were in remission. There was no significant association between any measure of cannabis use at baseline and either transition to psychosis, the persistence of symptoms, or functional outcome.ConclusionsThese findings contrast with epidemiological data that suggest that cannabis use increases the risk of psychotic disorder.

Funder

FP7 Ideas: European Research Council

Medical Research Centre

NIHR Maudsley Biomedical Research Centre

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical),Neurology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pcn.13555

Reference78 articles.

1. The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC)

2. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study

3. Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis

4. Cannabis use in young people: The risk for schizophrenia

5. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study